Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective long-term safety and efficacy study of CX401 in patients from FATT-1
2008-003140-10Phase 3Active
- Sponsor
- Cellerix, S.A.
- Start
- Jun 2008
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3 trial of CX401 in anal fistula (3 arms), sponsored by Cellerix, S.A. Primary endpoint: Incidence of therapy-attributed adverse events (clinical and laboratory). Started Jun 2008; status: active.
02
Drugs
CX401
03
Conditions
anal fistula
Beyond the preview
Go deeper on 2008-003140-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003140-10.